The stock of Kodiak Sciences Inc. (NASDAQ:KOD) reached all time high today, Jun, 11 and still has $11.83 target or 7.00 % above today’s $11.06 share price. This indicates more upside for the $407.97 million company. This technical setup was reported by Barchart.com. If the $11.83 PT is reached, the company will be worth $28.56M more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events.
The stock decreased 4.66% or $0.54 during the last trading session, reaching $11.06. About 144,802 shares traded or 60.96% up from the average. Kodiak Sciences Inc. (NASDAQ:KOD) has 0.00% since June 11, 2018 and is . It has underperformed by 4.43% the S&P500.
Analysts await Kodiak Sciences Inc. (NASDAQ:KOD) to report earnings on August, 21. After $-0.21 actual EPS reported by Kodiak Sciences Inc. for the previous quarter, Wall Street now forecasts 47.62 % negative EPS growth.
More notable recent Kodiak Sciences Inc. (NASDAQ:KOD) news were published by: Marketwatch.com which released: “Kodiak Sciences’ stock trades little changed in its debut, after the IPO prices well below the expected range – MarketWatch” on October 04, 2018, also 247Wallst.com with their article: “Top Analyst Upgrades and Downgrades: Amazon, Anheuser-Busch, Caterpillar, HUYA, Ligand Pharma, Verizon, Weyerhaeuser and More – 24/7 Wall St.” published on October 29, 2018, Fortune.com published: “Term Sheet — Friday, October 5 – Fortune” on October 05, 2018. More interesting news about Kodiak Sciences Inc. (NASDAQ:KOD) were released by: Nasdaq.com and their article: “Macular degeneration biotech Kodiak Sciences sets terms for $126 million IPO – Nasdaq” published on September 24, 2018 as well as Prnewswire.com‘s news article titled: “Kodiak Sciences Announces Completion of 12-Week Phase 1a Study of KSI-301 in Patients with Diabetic Macular Edema Demonstrating Safety and Durability of Responses Following Single Dose of Intravitreal Anti-VEGF Antibody Biopolymer Conjugate – PRNewswire” with publication date: December 21, 2018.
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, provides novel therapeutics to treat retinal diseases. The company has market cap of $407.97 million. The company’s lead product candidate is KSI-301, a vascular endothelial growth factor -biological agent that is in Phase I clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy. It currently has negative earnings. The Company’s preclinical stage product candidates include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases; KSI-201, a recombinant mammalian cell expressed dual inhibitor antibody biopolymer bioconjugate for the treatment of wet AMD; and KSI-401, a recombinant mammalian cell expressed antibody biopolymer conjugate for the treatment of dry AMD.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.